GSK's Bioelectronics R&D unit is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturised, implantable devices. 

GSK believes that these devices could be programmed to read and correct the electrical signals that pass along the nerves of the body, including irregular or altered impulses that can occur in association with a broad range of diseases. The hope is that through these devices, disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes could be treated.

In 2013, we outlined our vision for bioelectronic medicines in this commentary piece in Nature.

10 years from now - how will we fight disease?

At GSK we’re at the forefront of researching new ways to tackle some of the world’s biggest healthcare challenges. Like exploring the potential of bioelectronics to harness the electrical language of the body to treat disease.

Harnessing the electrical language of the body to treat disease

Bioelectronic medicine is a vision far from today’s medical practice. But we believe that one day, tiny devices, smaller than grains of rice, could be used to restore health in a range of chronic diseases centred on organs and biological functions.

Meet Daniel Chew

Hear from one of our bioelectronics researchers – “The future of medicine is electric”

Bioelectronics at SXSW 2016

We presented our work on bioelectronic medicine in a session called Inner Space: Bioelectronics and Medicine's Future

Working towards the development of bioelectronic medicines

Introducing Galvani Bioelectronics

Kris Famm, VP of Bioelectronics R&D, GSK, explains what bioelectronic medicines are all about

Dr. Moncef Slaoui, Bioelectronics Pioneer and Director/Chairman of Vaccines, talks about our innovative work on bioelectronic medicine